Bernard L Moss

US Patent:

6780417, Aug 24, 2004

Filed:

Mar 2, 1995

Appl. No.:

08/400421

Inventors:

David C. Kaslow - Kensington MD
Stuart Isaacs - Kensington MD
Bernard Moss - Bethesda MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39015

US Classification:

4241991, 4241911, 4242681, 4242721, 435 693, 4353201

Abstract:

The present invention relates to transmission blocking vaccines against malaria. Vaccines of the present invention contain a recombinant virus encoding all, or a unique portion, of the 25 kDa sexual stage surface protein of , Pfs25, or the Pfs25 protein purified from host cells infected with the above-described recombinant virus. Mice inoculated with the recombinant virus developed antibodies with transmission blocking activity. The present invention also relates to recombinant viruses used in the vaccines of the present invention, host cells infected with the recombinant viruses of the present invention and methods of preventing or treating malarial infections using the vaccines of the present invention.

US Patent:

6998252, Feb 14, 2006

Filed:

Jun 6, 1995

Appl. No.:

08/470360

Inventors:

Bernard Moss - Bethesda MD, US
Michael Mackett - Manchester, GB
Geoffrey L. Smith - Oxford, GB

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12N 15/863
C12N 7/01
C12N 15/64
C12N 15/09

US Classification:

435 691, 4353201, 4352351, 435 914, 435 9141, 435 693

Abstract:

Recombinant poxviruses, such as vaccinia, are provided that comprises a segment comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) said transcriptional regulatory sequence is adjacent to and exerts transcriptional control over said first DNA sequence and (ii) said segment is positioned within a nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells, and media comprising recombinant poxviruses, and methods of immunization with recombinant poxviruses also are provided.

US Patent:

7015024, Mar 21, 2006

Filed:

Jun 6, 1995

Appl. No.:

08/470357

Inventors:

Bernard Moss - Bethesda MD, US
Michael Mackett - Manchester, GB
Geoffrey L. Smith - Oxford, GB

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12N 7/01
C12N 5/10
A61K 39/275
A61K 39/285

US Classification:

4352351, 435325, 4353201, 4241991

Abstract:

Recombinant poxviruses, such as vaccinia, are provided that comprises a segment comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) said transcriptional regulatory sequence is adjacent to and exerts transcriptional control over said first DNA sequence and (ii) said segment is positioned within a nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells, and media comprising recombinant poxviruses, and methods of immunization with recombinant poxviruses, also are provided.

US Patent:

7045136, May 16, 2006

Filed:

Jun 6, 1995

Appl. No.:

08/470359

Inventors:

Bernard Moss - Bethesda MD, US
Michael Mackett - Manchester, GB
Geoffrey L. Smith - Oxford, GB

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/275
A61K 39/285

US Classification:

4241991, 4242321

Abstract:

Recombinant poxviruses, such as vaccinia, are provided that comprises a segment comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) said transcriptional regulatory sequence is adjacent to and exerts transcriptional control over said first DNA sequence and (ii) said segment is positioned within a nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells, and media comprising recombinant poxviruses, and methods of immunization with recombinant poxviruses also are provided.

US Patent:

7045313, May 16, 2006

Filed:

Dec 7, 1992

Appl. No.:

07/987546

Inventors:

Bernard Moss - Bethesda MD, US
Michael Mackett - Manchester, GB
Geoffrey Smith - Cambridge, GB

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12P 21/06

US Classification:

435 691, 4353201, 4352351, 435 914, 435 9141, 435 693

Abstract:

Methods and compositions are provided for the use of vaccinia virus or other poxviruses as vectors for expression of foreign genes. Expression of foreign genes is obtained by combining vaccinia virus transcriptional regulatory sequence with uninterrupted foreign protein coding sequences in vitro to form a chimeric gene. The chimeric gene is flanked by DNA from a non-essential region of the vaccinia virus genome to provide sites for in vivo homologous recombination. These steps are facilitated by the construction of plasmids that contain multiple restriction endonuclease sites, next to the vaccinia transcriptional regulatory sequences, for insertion of any foreign protein coding sequence. Transfection procedures are used to introduce the DNA into cells where homologous recombination results in the insertion of the chimeric gene into a non-essential region of the vaccinia virus genome. Infectious vaccinia virus recombinants are distinguished or selected by expression of the foreign gene, loss of activity of a vaccinia virus gene, or by DNA—DNA hybridization. Expression of the foreign gene is obtained by infecting cells or animals with the recombinant vaccinia virus.

US Patent:

7303754, Dec 4, 2007

Filed:

Sep 28, 2005

Appl. No.:

11/238155

Inventors:

Bernard Moss - Bethesda MD, US
Patricia L. Earl - Chevy Chase MD, US
Linda Wyatt - Rockville MD, US
Leigh Anne Eller - Kampala, UG
Thomas C. VanCott - Brookeville MD, US
Matthew Edward Harris - Poway CA, US

Assignee:

The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Rockville MD
The United States of America, as represented by the Secretary, Department of the Army - Washington DC

International Classification:

A61K 39/12

US Classification:

4242041, 4242051

Abstract:

The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.

US Patent:

7494813, Feb 24, 2009

Filed:

Oct 5, 2004

Appl. No.:

10/959392

Inventors:

Bernard Moss - Bethesda MD, US
Arban Domi - Rockville MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12N 15/10
C12N 15/63
C12N 15/64
C12N 15/70
C12N 15/863
C12N 1/21
A61K 48/00

US Classification:

435455, 4353201, 435456, 435457, 4352351, 435239, 4352523, 43525233

Abstract:

The invention relates to a VAC-BAC shuttle vector system for creation of recombinant poxviruses from DNA cloned in a bacterial artificial chromosome.

US Patent:

7867982, Jan 11, 2011

Filed:

Jan 22, 2008

Appl. No.:

12/018150

Inventors:

Bernard Moss - Bethesda MD, US
Linda Wyatt - Rockville MD, US
Patricia Earl - Chevy Chase MD, US
Harriet L. Robinson - Atlanta GA, US

Assignee:

Emory University - Atlanta GA

International Classification:

A61K 35/12
A61P 43/00

US Classification:

514 44, 530350

Abstract:

The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.